Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
Table 3
Frequencies and percentages of DRB1 alleles in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.
DRB1
HCV patients
Healthy controls
PC
Responders
Nonresponders
PC
()
()
()
()
*01
2 (3.2%)
6 (10.5%)
0.215
1 (2.4%)
1 (4.8%)
1.000
*0102
1 (1.6%)
9 (15.8%)
0.148
1 (2.4%)
0 (0.0%)
0.661
*0106
1 (1.6%)
1 (1.8%)
1.000
1 (2.4%)
0 (0.0%)
0.661
*03
13 (21.0%)
25 (43.9%)
0.072
11 (26.8%)
2 (9.5%)
0.187
*0301
8 (12.9%)
17 (29.8%)
0.552
6 (14.6%)
2 (9.5%)
0.447
*0304
4 (6.5%)
12 (21.1%)
0.112
2 (4.9%)
2 (9.5%)
0.417
*0313
5 (8.1%)
0 (0.0%)
0.222
3 (7.3%)
2 (9.5%)
0.556
*0328
8 (12.9%)
0 (0.0%)
0.183
6 (14.6%)
2 (9.5%)
0.447
*0332
3 (4.8%)
0 (0.0%)
0.556
1 (2.4%)
2 (9.5%)
0.263
*04
14 (22.6%)
12 (21.1%)
1.000
11 (26.8%)
3 (14.3%)
0.346
*0403
3 (4.8%)
13 (22.8%)
0.089
2 (4.9%)
1 (4.8%)
0.737
*0471
2 (3.2%)
7 (12.3%)
0.134
2 (4.9%)
0 (0.0%)
0.434
*0445
4 (6.5%)
9 (15.8%)
0.212
2 (4.9%)
2 (9.5%)
0.417
*07
22 (35.5%)
36 (63.2%)
0.029†
15 (36.6%)
7 (33.3%)
1.000
*0701
22 (35.5%)
36 (63.2%)
0.029†
13 (31.7%)
9 (42.9%)
0.277
*0703
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0705
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0706
4 (6.5%)
35 (61.4%)
0.000†
2 (4.9%)
2 (9.5%)
0.417
*0707
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0708
6 (9.7%)
35 (61.4%)
0.000†
3 (7.3%)
3 (14.3%)
0.325
*0709
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0710N
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0711
20 (32.3%)
36 (63.2%)
0.013†
13 (31.7%)
7 (33.3%)
0.558
*0712
4 (6.5%)
35 (61.4%)
0.000†
2 (4.9%)
2 (9.5%)
0.417
*0713
4 (6.5%)
35 (61.4%)
0.000†
2 (4.9%)
2 (9.5%)
0.417
*0714
6 (9.7%)
35 (61.4%)
0.000†
3 (7.3%)
3 (14.3%)
0.325
*08
4 (6.5%)
0 (0.0%)
0.570
3 (7.3%)
1 (4.8%)
1.000
*0801
2 (3.2%)
0 (0.0%)
0.434
1 (2.4%)
1 (4.8%)
0.661
*0816
2 (3.2%)
0 (0.0%)
0.434
1 (2.4%)
1 (4.8%)
0.566
*0833
1 (1.6%)
0 (0.0%)
1.000
1 (2.4%)
0 (0.0%)
0.661
*09
1 (1.6%)
0 (0.0%)
1.000
1 (2.4%)
0 (0.0%)
1.000
*0904
1 (1.6%)
0 (0.0%)
1.000
1 (2.4%)
0 (0.0%)
0.661
*0906
1 (1.6%)
0 (0.0%)
1.000
1 (2.4%)
0 (0.0%)
0.661
*10
3 (4.8%)
0 (0.0%)
0.282
3 (7.3%)
0 (0.0%)
0.545
*1001
3 (4.8%)
0 (0.0%)
0.282
3 (7.3%)
0 (0.0%)
0.282
*11
12 (19.4%)
7 (12.3%)
0.725
9 (22%)
3 (14.3%)
0.735
*1101
9 (14.5%)
22 (38.6%)
0.086
5 (12.2%)
4 (19%)
0.356
*1105
4 (6.5%)
8 (14%)
0.088
3 (7.3%)
1 (4.8%)
0.583
*1115
8 (12.9%)
3 (5.3%)
0.435
5 (12.2%)
3 (14.3%)
0.553
*1132
3 (4.8%)
3 (5.3%)
0.868
3 (7.3%)
0 (0.0%)
0.282
*1144
2 (3.2%)
6 (10.5)
0.358
1 (2.4%)
1 (4.8%)
0.566
*1166
1 (1.6%)
2 (3.5%)
0.586
0 (0.0%)
1 (4.8%)
0.339
*13
22 (35.5%)
3 (5.3%)
0.016†
19 (46.3%)
3 (14.3%)
0.014#
*1301
7 (11.3%)
12 (21.1%)
0.219
7 (17.1%)
0 (0%)
0.046#
*1303
7 (11.3%)
5 (8.8%)
0.525
5 (12.2%)
2 (9.5%)
0.558
*1361
7 (11.3%)
16 (28.1%)
0.079
7 (17.1%)
0 (0%)
0.046#
*1369
7 (11.3%)
3 (5.3%)
0.325
7 (17.1%)
0 (0%)
0.046#
*14
3 (4.8%)
0 (0.0%)
0.282
2 (4.9%)
1 (4.8%)
1.000
*1401
1 (1.6%)
0 (0.0%)
1.000
0 (0.0%)
1 (4.8%)
0.339
*1475
1 (1.6%)
0 (0.0%)
1.000
0 (0.0%)
1 (4.8%)
0.339
*15
11 (17.7%)
7 (12.3%)
0.722
10 (24.4%)
1 (4.8%)
0.048#
*1514
6 (9.7%)
3 (5.3%)
0.476
5 (12.2%)
1 (4.8%)
0.329
*1522
2 (3.2%)
9 (15.8%)
0.215
2 (4.9%)
0 (0.0%)
0.434
Significant difference at PC ≤ 0.05 between responder and nonresponder patients to treatment. †Significant difference at PC ≤ 0.05 (corrected P after the Bonferroni correction) between patients and healthy group. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “.”
